immuno-oncology

News

Boehringer buys cancer immunotherapy firm T3 for $507m

Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland.

News

Abecma delay gives Carvykti a chance to catch up

Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy f

News

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial

AstraZeneca’s cancer immunotherapy Imfinzi broke new ground when it was approved in 2018 for locally advanced non-small cell lung cancer (NSCLC) that can’t be treated with

News

BioNTech flashes the cash, adding tumour drug in $1bn deal

Fresh from slashing its predictions for COVID-19 vaccine sales this year, mRNA specialist BioNTech has used some of its extensive cash reserves to bolster its pipeline in

News

Imfinzi faces Keytruda competition in biliary tract cancer

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch

News

GSK claims a first with Jemperli in endometrial cancer

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.

Boehringer buys cancer immunotherapy firm T3 for $507m

Abecma delay gives Carvykti a chance to catch up

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial

BioNTech flashes the cash, adding tumour drug in $1bn deal

Imfinzi faces Keytruda competition in biliary tract cancer

GSK claims a first with Jemperli in endometrial cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

immuno-oncology

Editor's Picks